OPG, RANK and RANK ligand expression in thyroid lesions

Regulatory Peptides

Volumn 148, Issue 1-3, 2008, Pages 46-53

  Heymann, Marie Françoise ^a,b,c   Riet, Anne ^a,b   Le Goff, Benoît ^a,b,e   Battaglia, Séverine ^a,b   Paineau, Jacques ^d   Heymann, Dominique ^a,b,e  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c CHU de Nantes   (France)

^d CENTRE RENÉ GAUDUCHEAU   (France)

^e HÔTEL DIEU   (France)

Author keywords

Immunohistochemistry; Macrovesicular adenoma; Medullary carcinoma; OPG RANK RANKL; Papillary carcinoma; Thyroid

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MACROPHAGE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID ADENOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID PARAFOLLICULAR CELL; THYROID TUMOR;

EID: 44349107684     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2008.02.004     Document Type: Article

References (44)

1. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
2. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
3. Théoleyre S., Wittrant Y., Kwan Tat S., Fortun Y., Redini F., and Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 15 (2004) 457-475
4. Baud'huin M., Duplomb L., Ruiz Velasco C., Fortun Y., Heymann D., and Padrines M. Key roles of the OPG-RANK-RANKL system in bone oncology. Expert Res Anticancer Rev 7 (2007) 221-232
5. Baud'huin M., Lamoureux F., Duplomb L., Rédini F., and Heymann D. RANKL, RANK. Osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci 64 (2007) 2334-2350
6. Walsh M.C., Kim N., Kadono Y., Rho J., Lee S.Y., Lorenzo J., and Choi Y. Osteoimmunology: interplay between the immune system and bone metabolism. Ann Rev Immunol 24 (2006) 33-63
7. Hofbauer L.C., Kluger S., Kuhne C.A., Dunstan C.R., Burchert A., Schoppet M., Zeilke A., and Heufelder A.E. Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. J Cell Biochem 86 (2002) 642-650
8. Amato G., Mazziotti G., Sorvillo F., Piscopo M., Lalli E., Biondi B., Iorio S., Molinari A., Giustina A., and Carella C. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment. Bone 35 (2004) 785-791
9. Guang-da X., Hui-ling S., Zhi-song C., and Lin-shuang Z. Alteration of plasma concentrations of OPG before and after levothyroxine replacement therapy in hypothyroid patients. J Endocrinol Invest 28 (2005) 965-972
10. Nagasaki T., Inaba M., Jono S., Hiura Y., Tahara H., Shirakawa K., Onoda N., Ishikawa T., Ishimura E., and Nishizawa Y. Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function. Eur J Endocrinol 152 (2005) 347-353
11. Mochizuki Y., Banda N., Hattori Y., and Monden T. Correlation between serum osteoprotegerin and biomarkers of bone metabolim during anti-thyroid treatment in patients with Grave's disease. Horm Res 66 (2006) 236-239
12. Mikosch P., Igerc I., Kudlacek S., Woloszczuk W., Gallowitsch H.J., Kresnik E., Stettner H., Grimm G., Ling P., and Pietschmann P. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer. Eur J Clin Investig 36 (2006) 566-573
13. Grimaud E., Soubigou L., Couillaud S., Coipeau P., Moreau A., Passuti N., Gouin F., Redini F., and Heymann D. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163 (2003) 2021-2031
14. Mori K., Le Goff B., Berreur M., Riet A., Moreau A., Blanchard F., Chevalier C., Guisle-Marsollier I., Leger J., Guicheux J., Masson M., Gouin F., Redini F., and Heymann D. Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa. J Pathol 211 (2007) 555-562
15. Basset J.H., O'Shea P.J., Sriskantharajah S., Rabier B., Boyde A., Howell P.G., Weiss R.E., Roux J.P., Malaval L., Clement-Lacroix P., Samarut J., Chassande O., and Williams G.R. Thyroid hormone excess rather than thyrotropin deficiency induces otesoporosis in hyperthyroidism. Mol Endocrinol 21 (2007) 1095-1107
16. Miura M., Tanaka K., Komatsu Y., Suda M., Yasoda A., Sakuma Y., Ozasa A., and Nakao K. A novel interaction between thyroid hormones and 1,25(OH)(2)D(3) in osteoclast formation. Biochem Biophys Res Commun 291 (2002) 987-994
17. Kawaguchi H., Pilbeam C.C., Woodiel F.N., and Rasiz L.G. Comparison of the effects of 3,5,3′-triiodothyroacetic acid and triiodothyronine on bone resorption in cultured fetal rat long bones and neonatal mouse calvariae. J Bone Miner Res 9 (1994) 247-253
18. Rooman R.P., Kuijpers G., Gresnigt R., Bloemen R., Koster J.G., and van Buul-Offers S.C. Dexamethasone differentially inhibits thyroxine- or growth hormone-induced body and organ growth of snell dwarf mice. Endocrinology 144 (2003) 2553-2558
19. Göthe S., Wang Z., Ng L., Kindblom J.M., Barros A.C., Ohlsson C., Vennström B., and Forrest D. Mice devoid of all known thyroid hormone receptors are viable but exhibit disorders of the pituitary-thyroid axis, growth, and bone maturation. Genes Dev 13 (1999) 1329-1341
20. Findlay D.M., and Sexton P.M. Calcitonin. Growth Factors 22 (2004) 217-222
21. Varga F., Spitzer S., and Klaushofer K. Triiodothyronine (T3) and 1,25-dihydroxyvitamine D3 (1,25D3) inversely regulate OPG gene expression in independance of the osteoblastic phenotype. Calcif Tissue Int 74 (2004) 382-387
22. Kanatani M., Sugimoto T., Sowa H., Kobayashi T., Kanzawa M., and Chihara K. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction. J Cell Physiol 201 (2004) 17-25
23. Mazziotti G., Sorvillo F., Piseopo M., Cioffi M., Pilla P., Biondi B., Iorio S., Giustina A., Amato G., and Carella C. Recombinant TSH modulates in vivo c-telopeptides of type-1 collagen and bone alkaline phosphatise, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma. J Bone Miner Res 20 (2005) 480-486
24. Abe E., Marians R.C., Yu W., Wu X.B., Ando T., Li Y., Iqbal J., Eldeiry L., Rajendren G., Blair H.C., Davies T.F., and Zaidi M. TSH is a negative regulator of skeletal remodelling. Cell 115 (2003) 151-162
25. Sampath T.K., Simic P., Sendak R., Draca N., Bowe A.E., O'Brien S., Schiavi S.C., PcPherson J.M., and Vukicevic S. Thyroid stimulating hormone (TSH) restores bone volume microarchitecture and strength is aged ovariectomized rats. J Bone Miner Res 22 (2007) 849-859
26. Kudlacek S., Schneider B., Woloszczuk W., Pietschmann P., and Willvonseder R. Austrian Study Group on Normative Values of Bone Metabolism. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 32 (2003) 681-686
27. Ueland T., Brixen K., Mosekilde L., Flyybjerg A., and Bollersley J. Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. J Clin Endocrinol Metab 88 (2003) 1014-1018
28. Giusti M., Cecoli F., Fazzuoli L., De Franchis V., Ceresola E., Ferone D., Mussap M., and Minuto F. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study. Metabolism 56 (2007) 699-707
29. Terpos E., Szydlo R., Apperley J.F., Hatjiharissi E., Politou M., Meletis J., Viniou N., Yataganas X., Goldman J.M., and Rahemtulla A. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102 (2003) 1064-1069
30. Lin S.Y., Makino K., Xia W., Matin A., Wen Y., Kwong K.Y., Bourguignon L., and Hung M.C. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3 (2001) 802-808
31. Zhang X.D., Franco A.V., Nguyen T., Gray C.P., and Hersey P. Differential localization and regulation of death and decoy receptors for TNF-related apoptosis-inducing ligand (TRAIL) in human melanoma cells. J Immunol 164 (2000) 3961-3970
32. Lin-Lee Y.C., Pham L.V., Tamayo A.T., Fu L., Zhou H.J., Yoshimura L.C., Decker G.L., and Ford R.J. Nuclear localization in the biology of the CD40 receptor in normal and neoplastic human B lymphocytes. J Biol Chem 281 (2006) 18878-18887
33. Min W., Bradley J.R., Galbraith J.J., Jones S.J., Ledgerwood E.C., and Pober J.S. The N-terminal domains target TNF receptor-associated factor-2 to the nucleus and display transcriptional regulatory activity. J Immunol 161 (1998) 319-324
34. Anest V., Hanson J.L., Cogswell P.C., Steinbrecher K.A., Strahl B.D., and Baldwin A.S. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 423 (2003) 659-663
35. Wells A., and Marti U. Signalling shortcuts: cell-surface receptors in the nucleus?. Nat Rev Mol Cell Biol 3 (2002) 697-702
36. Jones D.H., Nakashima T., Sanchez O.H., Kozieradzki I., Komarova S.V., Sarosi I., Morony S., Rubin E., Sarao R., Hojilla C.V., Komnenovic V., Kong Y.Y., Schreiber M., Dixon S.J., Sims S.M., Khokha R., Wada T., and Penninger J.M. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440 (2006) 692-696
37. Mori K., Le Goff B., Charrier C., Battaglia S., Heymann D., and Rédini F. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process. Bone 40 (2007) 981-990
38. Mori K., Berreur M., Blanchard F., Chevalier C., Guisle-Marsollier I., Masson M., Rédini F., and Heymann D. Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells. Oncol Rep 18 (2007) 1365-1371
39. Lamoureux F., Richard P., Wittrant Y., Battaglia S., Pilet P., Trichet V., Pitard B., Heymann D., and Rédini F. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: prevention of bone resorption, inhibition of tumor progression, increase of animal survival. Cancer Res 67 (2007) 7308-7318
40. Bhatia P., Sanders M.M., and Hansen M.F. Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res 11 (2005) 162-165
41. Do M.Y., Rhee Y., Kim D.J., Kim C.S., Nam K.H., Ahn C.W., Cha B.S., Kim K.R., Lee H.C., Park C.S., and Lim S.K. Clinical features of bone metastases resulting from thyroid cancer: a review of 28 patients over a 20-year period. Endocrinol J 52 (2005) 701-707
42. Mosheimer B.A., Kaneider N.C., Feistritzer C., Djanani A.M., Sturn D.H., Patsch J.R., and Wiedermann C.J. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab 90 (2005) 2964-2971
43. Mosheimer B.A., Kaneider N.C., Feistritzer C., Sturn D.H., and Wiedermann C.J. Expression and function of RANK in human monocyte chemotaxis. Arthritis Rheum 50 (2004) 2309-2316
44. Mangan S.H., Campenhout A.V., Rush C., and Golledge J. Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc Res 76 (2007) 494-505